Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys, a manufacturer of therapeutic antibodies, has expanded its license agreement with Shionogi of Japan, which includes the use of MorphoSys's HuCAL antibody technology and additional proprietary technology modules for research in drug discovery.
Subscribe to our email newsletter
The research will be run by the company’s AbD Serotec unit for three additional years.
As per the deal, Shionogi will continue to have the right to use MorphoSys’s patented antibody library HuCAL Platinum for research purposes and will pay annual user fees to MorphoSys for access to the technologies.
AbD Serotec senior vice president Dieter Feger said Shionogi’s commitment to HuCAL as a research tool proves the clear scientific and commercial potential of therapeutic antibodies.
MorphoSys and Shionogi entered the first license agreement on the use of MorphoSys’s HuCAL technology in September 2005.